Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Aurangabad, India facility. The inspection for the facility was carried out by the USFDA between February 10, 2020 and February 14, 2020 and concluded with no observations.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.